Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.51 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.46 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25970053 | 0.90 | KIF11 (0.47) | KIF11SLC6A1SLC6A11MEN1KMT2A | |
| SCHEMBL4794864 | 0.88 | TK1 (0.45) | KIF11SLC6A1ALDH1A1 | |
| SCHEMBL23215946 | 0.88 | TK1 (0.45) | KIF11SLC6A1ALDH1A1 | |
| SCHEMBL23216478 | 0.88 | TK1 (0.45) | KIF11SLC6A1ALDH1A1 | |
| SCHEMBL10434128 | 0.84 | LMNA (0.46) | KIF11SLC6A1SLC6A11MEN1KMT2A | |
| SCHEMBL24937040 | 0.84 | LMNA (0.46) | KIF11SLC6A1SLC6A11MEN1KMT2A | |
| SCHEMBL10434091 | 0.84 | LMNA (0.46) | KIF11SLC6A1SLC6A11MEN1KMT2A | |
| SCHEMBL13388489 | 0.82 | KIF11 (0.50) | KIF11SLC6A1SLC6A11KCNH2 | |
| SCHEMBL30056424 | 0.82 | KIF11 (0.48) | KIF11SLC6A1SLC6A11MEN1KMT2A | |
| SCHEMBL17423858 | 0.82 | KIF11 (0.50) | KIF11SLC6A1SLC6A11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230313195-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230287418-A1 | MODIFIED SIRNA WITH REDUCED OFF-TARGET ACTIVITY | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-09-14 | — | — | US | disclosed |
| US-20230193277-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230193277-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | F13A1, F13B, F11 | KIF11 90/4885SLC6A1 3426/4885SLC6A11 1983/4885 |
| US-20230313195-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | PCSK9, PCSK7, PCSK6 | KIF11 398/4885SLC6A1 4380/4885SLC6A11 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.